Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Non-small Cell Lung Cancer Drugs Revenue 1.4 Market Analysis by Type 1.4.1 Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Biologics 1.4.3 Small Molecule Targeted Therapy 1.4.4 Chemotherapy 1.4.5 Other 1.5 Market by Application 1.5.1 Global Non-small Cell Lung Cancer Drugs Market Share by Application: 2020 VS 2026 1.5.2 Lung Adenocarcinoma 1.5.3 Squamous Cell Lung Carcinoma 1.5.4 Large-cell Lung Carcinoma 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Non-small Cell Lung Cancer Drugs Market Perspective (2015-2026) 2.2 Non-small Cell Lung Cancer Drugs Growth Trends by Regions 2.2.1 Non-small Cell Lung Cancer Drugs Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Non-small Cell Lung Cancer Drugs Historic Market Share by Regions (2015-2020) 2.2.3 Non-small Cell Lung Cancer Drugs Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Non-small Cell Lung Cancer Drugs Market Growth Strategy 2.3.6 Primary Interviews with Key Non-small Cell Lung Cancer Drugs Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Non-small Cell Lung Cancer Drugs Players by Market Size 3.1.1 Global Top Non-small Cell Lung Cancer Drugs Players by Revenue (2015-2020) 3.1.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Players (2015-2020) 3.1.3 Global Non-small Cell Lung Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio 3.2.1 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Drugs Revenue in 2019 3.3 Non-small Cell Lung Cancer Drugs Key Players Head office and Area Served 3.4 Key Players Non-small Cell Lung Cancer Drugs Product Solution and Service 3.5 Date of Enter into Non-small Cell Lung Cancer Drugs Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Type (2015-2020) 4.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Type (2021-2026) 5 Non-small Cell Lung Cancer Drugs Breakdown Data by Application (2015-2026) 5.1 Global Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) 5.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Non-small Cell Lung Cancer Drugs Market Size (2015-2020) 6.2 Non-small Cell Lung Cancer Drugs Key Players in North America (2019-2020) 6.3 North America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) 6.4 North America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) 7 Europe 7.1 Europe Non-small Cell Lung Cancer Drugs Market Size (2015-2020) 7.2 Non-small Cell Lung Cancer Drugs Key Players in Europe (2019-2020) 7.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) 7.4 Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) 8 China 8.1 China Non-small Cell Lung Cancer Drugs Market Size (2015-2020) 8.2 Non-small Cell Lung Cancer Drugs Key Players in China (2019-2020) 8.3 China Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) 8.4 China Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) 9 Japan 9.1 Japan Non-small Cell Lung Cancer Drugs Market Size (2015-2020) 9.2 Non-small Cell Lung Cancer Drugs Key Players in Japan (2019-2020) 9.3 Japan Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) 9.4 Japan Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size (2015-2020) 10.2 Non-small Cell Lung Cancer Drugs Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) 10.4 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) 11 India 11.1 India Non-small Cell Lung Cancer Drugs Market Size (2015-2020) 11.2 Non-small Cell Lung Cancer Drugs Key Players in India (2019-2020) 11.3 India Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) 11.4 India Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Non-small Cell Lung Cancer Drugs Market Size (2015-2020) 12.2 Non-small Cell Lung Cancer Drugs Key Players in Central & South America (2019-2020) 12.3 Central & South America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) 12.4 Central & South America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) 13Key Players Profiles 13.1 AstraZeneca 13.1.1 AstraZeneca Company Details 13.1.2 AstraZeneca Business Overview and Its Total Revenue 13.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Introduction 13.1.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020)) 13.1.5 AstraZeneca Recent Development 13.2 Bristol-Myers Squibb Company 13.2.1 Bristol-Myers Squibb Company Company Details 13.2.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue 13.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Introduction 13.2.4 Bristol-Myers Squibb Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) 13.2.5 Bristol-Myers Squibb Company Recent Development 13.3 Eli Lilly and Company 13.3.1 Eli Lilly and Company Company Details 13.3.2 Eli Lilly and Company Business Overview and Its Total Revenue 13.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Introduction 13.3.4 Eli Lilly and Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) 13.3.5 Eli Lilly and Company Recent Development 13.4 F. Hoffmann-La Roche Ltd 13.4.1 F. Hoffmann-La Roche Ltd Company Details 13.4.2 F. Hoffmann-La Roche Ltd Business Overview and Its Total Revenue 13.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Introduction 13.4.4 F. Hoffmann-La Roche Ltd Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) 13.4.5 F. Hoffmann-La Roche Ltd Recent Development 13.5 Merck & Co., Inc. 13.5.1 Merck & Co., Inc. Company Details 13.5.2 Merck & Co., Inc. Business Overview and Its Total Revenue 13.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Introduction 13.5.4 Merck & Co., Inc. Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) 13.5.5 Merck & Co., Inc. Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Non-small Cell Lung Cancer Drugs Key Market Segments Table 2. Key Players Covered: Ranking by Non-small Cell Lung Cancer Drugs Revenue Table 3. Ranking of Global Top Non-small Cell Lung Cancer Drugs Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Biologics Table 6. Key Players of Small Molecule Targeted Therapy Table 7. Key Players of Chemotherapy Table 8. Key Players of Other Table 9. Global Non-small Cell Lung Cancer Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 10. Global Non-small Cell Lung Cancer Drugs Market Size by Regions (US$ Million): 2020 VS 2026 Table 11. Global Non-small Cell Lung Cancer Drugs Market Size by Regions (2015-2020) (US$ Million) Table 12. Global Non-small Cell Lung Cancer Drugs Market Share by Regions (2015-2020) Table 13. Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 14. Global Non-small Cell Lung Cancer Drugs Market Share by Regions (2021-2026) Table 15. Market Top Trends Table 16. Key Drivers: Impact Analysis Table 17. Key Challenges Table 18. Non-small Cell Lung Cancer Drugs Market Growth Strategy Table 19. Main Points Interviewed from Key Non-small Cell Lung Cancer Drugs Players Table 20. Global Non-small Cell Lung Cancer Drugs Revenue by Players (2015-2020) (Million US$) Table 21. Global Non-small Cell Lung Cancer Drugs Market Share by Players (2015-2020) Table 22. Global Top Non-small Cell Lung Cancer Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-small Cell Lung Cancer Drugs as of 2019) Table 23. Global Non-small Cell Lung Cancer Drugs by Players Market Concentration Ratio (CR5 and HHI) Table 24. Key Players Headquarters and Area Served Table 25. Key Players Non-small Cell Lung Cancer Drugs Product Solution and Service Table 26. Date of Enter into Non-small Cell Lung Cancer Drugs Market Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$) Table 29. Global Non-small Cell Lung Cancer Drugs Market Size Share by Type (2015-2020) Table 30. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Non-small Cell Lung Cancer Drugs Market Size Share by Application (2015-2020) Table 32. Global Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$) Table 33. Global Non-small Cell Lung Cancer Drugs Market Size Share by Application (2021-2026) Table 34. North America Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$) Table 35. North America Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020) Table 36. North America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$) Table 37. North America Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020) Table 38. North America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$) Table 39. North America Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020) Table 40. Europe Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$) Table 41. Europe Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020) Table 42. Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$) Table 43. Europe Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020) Table 44. Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$) Table 45. Europe Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020) Table 46. China Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$) Table 47. China Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020) Table 48. China Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$) Table 49. China Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020) Table 50. China Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$) Table 51. China Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020) Table 52. Japan Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$) Table 53. Japan Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020) Table 54. Japan Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$) Table 55. Japan Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020) Table 56. Japan Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$) Table 57. Japan Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020) Table 58. Southeast Asia Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$) Table 59. Southeast Asia Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020) Table 60. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$) Table 61. Southeast Asia Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020) Table 62. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$) Table 63. Southeast Asia Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020) Table 64. India Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$) Table 65. India Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020) Table 66. India Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$) Table 67. India Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020) Table 68. India Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$) Table 69. India Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020) Table 70. Central & South America Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$) Table 71. Central & South America Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020) Table 72. Central & South America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$) Table 73. Central & South America Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020) Table 74. Central & South America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$) Table 75. Central & South America Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020) Table 76. AstraZeneca Company Details Table 77. AstraZeneca Business Overview Table 78. AstraZeneca Product Table 79. AstraZeneca Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$) Table 80. AstraZeneca Recent Development Table 81. Bristol-Myers Squibb Company Company Details Table 82. Bristol-Myers Squibb Company Business Overview Table 83. Bristol-Myers Squibb Company Product Table 84. Bristol-Myers Squibb Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$) Table 85. Bristol-Myers Squibb Company Recent Development Table 86. Eli Lilly and Company Company Details Table 87. Eli Lilly and Company Business Overview Table 88. Eli Lilly and Company Product Table 89. Eli Lilly and Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$) Table 90. Eli Lilly and Company Recent Development Table 91. F. Hoffmann-La Roche Ltd Company Details Table 92. F. Hoffmann-La Roche Ltd Business Overview Table 93. F. Hoffmann-La Roche Ltd Product Table 94. F. Hoffmann-La Roche Ltd Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$) Table 95. F. Hoffmann-La Roche Ltd Recent Development Table 96. Merck & Co., Inc. Company Details Table 97. Merck & Co., Inc. Business Overview Table 98. Merck & Co., Inc. Product Table 99. Merck & Co., Inc. Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$) Table 100. Merck & Co., Inc. Recent Development Table 101. Research Programs/Design for This Report Table 102. Key Data Information from Secondary Sources Table 103. Key Data Information from Primary Sources List of Figures Figure 1. Global Non-small Cell Lung Cancer Drugs Market Share by Type: 2020 VS 2026 Figure 2. Biologics Features Figure 3. Small Molecule Targeted Therapy Features Figure 4. Chemotherapy Features Figure 5. Other Features Figure 6. Global Non-small Cell Lung Cancer Drugs Market Share by Application: 2020 VS 2026 Figure 7. Lung Adenocarcinoma Case Studies Figure 8. Squamous Cell Lung Carcinoma Case Studies Figure 9. Large-cell Lung Carcinoma Case Studies Figure 10. Non-small Cell Lung Cancer Drugs Report Years Considered Figure 11. Global Non-small Cell Lung Cancer Drugs Market Size YoY Growth 2015-2026 (US$ Million) Figure 12. Global Non-small Cell Lung Cancer Drugs Market Share by Regions: 2020 VS 2026 Figure 13. Global Non-small Cell Lung Cancer Drugs Market Share by Regions (2021-2026) Figure 14. Porter's Five Forces Analysis Figure 15. Global Non-small Cell Lung Cancer Drugs Market Share by Players in 2019 Figure 16. Global Top Non-small Cell Lung Cancer Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-small Cell Lung Cancer Drugs as of 2019 Figure 17. The Top 10 and 5 Players Market Share by Non-small Cell Lung Cancer Drugs Revenue in 2019 Figure 18. North America Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 19. Europe Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 20. China Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 21. Japan Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 23. India Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Central & South America Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 25. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. AstraZeneca Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020) Figure 27. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. Bristol-Myers Squibb Company Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020) Figure 29. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Eli Lilly and Company Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020) Figure 31. F. Hoffmann-La Roche Ltd Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020) Figure 33. Merck & Co., Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. Merck & Co., Inc. Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020) Figure 35. Bottom-up and Top-down Approaches for This Report Figure 36. Data Triangulation Figure 37. Key Executives Interviewed

AstraZeneca Bristol-Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd Merck & Co., Inc.